BGNE240920C170000
- 24.00
- 0.000.00%
BeiGene Newsroom
Merck, Bristol Myers Cancer Drugs Included in September FDA Advisory Panel Meeting
Beigene (06160) class 1 new drug BGB-43395 tablet approved for clinical use in breast cancer and other solid tumors.
On August 22nd, the official website of China National Medical Products Administration (NMPA) Drug Evaluation Center (CDE) announced that Beigene (06160) has received clinical approval for the first class of new drug BGB-43395 tablets. It is intended to be used for monotherapy or in combination with fluorouracil and vinorelbine or other drugs for the treatment of advanced or metastatic HR+/HER2- breast cancer and other solid tumors.
HKEX abnormal movement| BeiGene (06160) rose nearly 3% in the morning, and many innovative drug companies welcomed their mid-year reports with joy. The company's BTK drug market share continues to expand in the United States.
Beigene (06160) rose nearly 3% in the morning. As of press time, it rose 2.82% to HKD 120.5, with a turnover of HKD 90.0317 million.
BeiGene Is Maintained at Overweight by JP Morgan
Express News | JP Morgan Maintains Overweight on BeiGene, Raises Price Target to $200
BeiGene Analyst Ratings
J.P. Morgan Maintains BeiGene(BGNE.US) With Buy Rating, Raises Target Price to $200
Express News | Beigene : JP Morgan Raises Target Price to $200 From $194
TD Cowen Initiates BeiGene(BGNE.US) With Buy Rating, Announces Target Price $254
TD Cowen Sticks to Its Buy Rating for BeiGene (BGNE)
BeiGene, Ltd. (NASDAQ:BGNE) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Top Gap Ups and Downs on Friday: SONY, IBN, DEO and More
Jefferies Maintains BeiGene(BGNE.US) With Buy Rating, Raises Target Price to $284
Jefferies Sticks to Their Buy Rating for BeiGene (BGNE)
Monkeypox epidemic is fermenting! Biomedical stocks on the Hong Kong stock market continue to be active. Institutions are expected to see a concentrated bullish catalyst.
Which mid-term bullish trends are worth paying attention to in the continuously active Hong Kong biomedical sector? What are the highlights of the Wande Innovative Drugs Index outperforming the market since July?
BeiGene Announces New Stock Incentives
Innovative drug concepts are generally rising, Beigene (06160) rose 3.14%. Institutions pointed out that overseas authorization and heavy innovation will be the catalyst for industry investment.
Innovative drug concept rose, Remegen (09995) rose by 4.14%, Beigene (06160) rose by 3.14%, Akeso (09926) rose by 1.84%, Innovent bio (01801) rose by 1.82%, Hutchmed (china) (00013) rose by 1.82%, Frontage (01521) rose by 1.35%, Canbridge Life Sciences-B (02162) rose by 0.63%, Innocare (09969) rose by 0.45%. Sinolink Securities indicated that the performance of the innovative drug companies has shown a clear trend of improvement based on the disclosed interim reports. Beigene and Hutchmed (china) pharmaceutical both performed well.
Party Time: Brokers Just Made Major Increases To Their BeiGene, Ltd. (NASDAQ:BGNE) Earnings Forecasts
BeiGene Confirms Information Accuracy, Seeks Exemptions
BeiGene Schedules Key Financial Review Meeting